ZA200401004B - Combination for the treatment of inflammatory disorders - Google Patents

Combination for the treatment of inflammatory disorders

Info

Publication number
ZA200401004B
ZA200401004B ZA200401004A ZA200401004A ZA200401004B ZA 200401004 B ZA200401004 B ZA 200401004B ZA 200401004 A ZA200401004 A ZA 200401004A ZA 200401004 A ZA200401004 A ZA 200401004A ZA 200401004 B ZA200401004 B ZA 200401004B
Authority
ZA
South Africa
Prior art keywords
treatment
combination
inflammatory disorders
disorders
inflammatory
Prior art date
Application number
ZA200401004A
Other languages
English (en)
Inventor
Robyn Sackeyfio
Jason Fong
Nicole Hurst
Palaniyandi Manivasakam
Edward R Jostp-Price
Grant Zimmerman
Curtis Keith
Alexis Borisy
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23174998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200401004(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of ZA200401004B publication Critical patent/ZA200401004B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
ZA200401004A 2001-07-09 2004-02-06 Combination for the treatment of inflammatory disorders ZA200401004B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30408901P 2001-07-09 2001-07-09

Publications (1)

Publication Number Publication Date
ZA200401004B true ZA200401004B (en) 2006-03-29

Family

ID=23174998

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200401004A ZA200401004B (en) 2001-07-09 2004-02-06 Combination for the treatment of inflammatory disorders

Country Status (23)

Country Link
US (5) US6897206B2 (hr)
EP (1) EP1414466B1 (hr)
JP (1) JP2004534841A (hr)
KR (1) KR20040026680A (hr)
CN (1) CN1553804A (hr)
AR (1) AR034746A1 (hr)
AT (1) ATE439844T1 (hr)
AU (1) AU2002310511B2 (hr)
BR (1) BR0211062A (hr)
CA (1) CA2453399A1 (hr)
DE (1) DE60233414D1 (hr)
ES (1) ES2330837T3 (hr)
HR (1) HRP20040102A2 (hr)
IL (1) IL159771A0 (hr)
IS (1) IS7099A (hr)
MX (1) MXPA04000222A (hr)
NO (1) NO20040097L (hr)
NZ (1) NZ530764A (hr)
PL (1) PL368045A1 (hr)
RU (1) RU2300379C2 (hr)
SG (1) SG152907A1 (hr)
WO (1) WO2003006026A1 (hr)
ZA (1) ZA200401004B (hr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159771A0 (en) * 2001-07-09 2004-06-20 Combinatorx Inc Combinations for the treatment of inflammatory disorders
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7264933B2 (en) 2003-03-26 2007-09-04 Synergy Biosystems Ltd Methods to identify biologically active agents and synergistic combinations
EP1675550A4 (en) * 2003-09-24 2007-10-10 Combinatorx Inc THERAPEUTIC DOSAGE DIAGRAMS FOR ADMINISTRATION OF MEDICINAL COMBINATIONS
EP1666068A4 (en) * 2003-09-24 2010-08-04 Santen Pharmaceutical Co Ltd REMEDY FOR EYE DISEASES ACCOMPANIED BY OPTICAL NERVE INJURIES
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
RU2006120408A (ru) * 2003-11-13 2007-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы и реагенты для лечения воспалительных нарушений
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
JP5905183B2 (ja) 2004-05-12 2016-04-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 感染を処置するためのゲルソリンの使用
CN1980649A (zh) * 2004-05-17 2007-06-13 康宾纳特克斯公司 治疗免疫炎性疾病的方法和试药
WO2006006152A2 (en) * 2004-07-08 2006-01-19 Ramot At Tel-Aviv University Ltd Treatment of disorders and diseases of the colon
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
US20070299043A1 (en) * 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
US20070196421A1 (en) * 2005-10-03 2007-08-23 Hunter William L Soft tissue implants and drug combination compositions, and use thereof
EP2177621B1 (en) 2006-01-10 2013-10-09 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
WO2007100937A2 (en) * 2006-01-19 2007-09-07 The Regents Of The University Of Michigan System and method for spectroscopic photoacoustic tomography
PT3279663T (pt) * 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
WO2007139753A2 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
WO2008084064A1 (en) * 2007-01-09 2008-07-17 Fovea Pharmaceuticals Apparatus for intra-ocular injection
GB0701170D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
TW200902032A (en) * 2007-03-26 2009-01-16 Combinatorx Inc Split dose corticosteroid therapy
CN101720186A (zh) * 2007-04-30 2010-06-02 阿得罗公司 (-)-e-10-oh-nt组合物及其合成与使用的方法
US20110009351A1 (en) * 2007-05-09 2011-01-13 Traffick Therepeutics Inc. Screening assay to identify correctors of protein trafficking defects
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
NZ597767A (en) 2007-05-21 2013-06-28 Bristol Myers Squibb Co Antibodies to IL-6 and use thereof
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9511076B2 (en) * 2008-05-30 2016-12-06 Clarion Research Group Formulations and methods for recovery from dental surgery
GB0715428D0 (en) * 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
NZ586332A (en) * 2007-12-17 2012-07-27 Zalicus Inc Therapeutic regimens for the treatment of immunoinflammatory disorders using dipyridamole and prednisolone
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
DK2262506T3 (da) * 2008-03-11 2014-06-10 Alcon Res Ltd Meget flokkulerede triamcinolonacetonid-suspensioner med lav viskositet til intravitreal injektion
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
ES2402084T3 (es) 2008-06-20 2013-04-26 Astrazeneca Ab Derivado de dibenzotiazepina y sus usos
EP2309858A4 (en) * 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
GB2463883A (en) * 2008-09-25 2010-03-31 Pharma Patents Ltd A pharmaceutical composition comprising an A-SMase inhibitor and an NO-donor
WO2010048264A2 (en) * 2008-10-23 2010-04-29 Combinatorx, Incorporated Methods and compositions for the treatment of immunoinflammatory disorders
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8992920B2 (en) * 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
US9468676B2 (en) 2009-11-24 2016-10-18 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
AR081772A1 (es) * 2010-06-02 2012-10-17 Ab Science Tratamiento de la artritis reumatoide con masitinib
WO2012071554A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
WO2022015423A1 (en) 2020-07-16 2022-01-20 Dermavant Sciences GmbH ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2900249A (en) * 1956-06-01 1959-08-18 United States Steel Corp Surface blowing process for making steel
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4107306A (en) * 1973-01-16 1978-08-15 The Regents Of The University Of Michigan Process for treating proliferative skin disease
WO1995031722A1 (en) * 1994-05-18 1995-11-23 Ligand Pharmaceuticals, Inc. Screening for cytokine modulators
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
US5900249A (en) 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
IL159771A0 (en) 2001-07-09 2004-06-20 Combinatorx Inc Combinations for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
EP1414466A1 (en) 2004-05-06
MXPA04000222A (es) 2004-05-04
AR034746A1 (es) 2004-03-17
DE60233414D1 (de) 2009-10-01
JP2004534841A (ja) 2004-11-18
HRP20040102A2 (en) 2004-10-31
WO2003006026A1 (en) 2003-01-23
IS7099A (is) 2004-01-08
CA2453399A1 (en) 2003-01-23
US6897206B2 (en) 2005-05-24
IL159771A0 (en) 2004-06-20
US6955815B2 (en) 2005-10-18
SG152907A1 (en) 2009-06-29
US20080280863A1 (en) 2008-11-13
US20030078246A1 (en) 2003-04-24
RU2300379C2 (ru) 2007-06-10
KR20040026680A (ko) 2004-03-31
PL368045A1 (en) 2005-03-21
US7335371B2 (en) 2008-02-26
AU2002310511B2 (en) 2007-12-06
BR0211062A (pt) 2004-07-20
ATE439844T1 (de) 2009-09-15
RU2004103537A (ru) 2005-02-27
CN1553804A (zh) 2004-12-08
EP1414466B1 (en) 2009-08-19
EP1414466A4 (en) 2006-06-07
AU2002310511B8 (en) 2003-01-29
NZ530764A (en) 2008-07-31
US20040116395A1 (en) 2004-06-17
US20040110734A1 (en) 2004-06-10
ES2330837T3 (es) 2009-12-16
NO20040097L (no) 2004-03-01
US20100173881A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
ZA200401004B (en) Combination for the treatment of inflammatory disorders
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
IL209842A0 (en) Compounds for the treatment of metabolic disorders
SI1474416T1 (sl) Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj
IL157734A0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
GB0007193D0 (en) Treatment of movrmrnt disorders
AU2003274342A8 (en) Compositions for the treatment of autoimmune disorders
IL153425A0 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
IL160852A0 (en) Pharmaceutical compositions for the treatment of urinary disorders
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
AU8339301A (en) Compounds for the treatment of addictive disorders
GB0127206D0 (en) Treatment of inflammatory conditions
HRP20041159A2 (en) Combination for the treatment of airway disorders
GB9816352D0 (en) The treatment of inflammatory disorders
GB9816349D0 (en) The treatment of inflammatory disorders